Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke
Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke
The purpose of this study is to provide a description of blood flow changes in the brain
 after blood pressure lowering drugs are given. This information will be used by physicians to
 guide blood pressure lowering therapy in stroke patients in the future.
Objective: To elucidate the inter-relationships between blood pressure (BP), cerebral blood
 flow (CBF) and oxygen metabolism in acute ischemic stroke in order to establish rational
 acute hypertension treatment thresholds.

 Background: Management of acute hypertension in the first 48 hours after stroke is
 controversial and lends itself to competing rationales. Early reduction of BP may improve
 outcome by reducing the rate of hemorrhagic transformation and edema formation in early
 infarcts. Conversely, early BP reduction might reduce CBF and extend the infarct. Natural
 history studies have demonstrated that patients with higher BP at presentation have elevated
 early mortality rates, but causality has not been established. Consensus-based guidelines for
 acute BP management are not based on physiological data or sound evidence. The investigators
 propose to start addressing this clinical dilemma with a non-randomized controlled study of
 serial measurements of CBF and oxygen metabolism in acute stroke patients with 3 different
 levels of acute blood pressure representing 3 different potential treatment thresholds.

 Hypothesis: The investigators hypothesize that the volume and severity of oligemia in at risk
 tissue will not increase with BP reduction in acute stroke patients.

 Specific Aims:

 1. Determine the effect of mean arterial pressure (MAP) decreases on CBF.

 2. Determine the relationship between infarct volume change over time and MAP.

 3. Determine the frequency of hemorrhagic transformation and its relationship to MAP.

 Study Design: A 3 group non-randomized controlled study. After informed consent, all patients
 will undergo MRI scanning including diffusion and perfusion-weighted imaging (DWI and PWI).
 Patients with MAP <100 mmHg will not receive hypertension treatment. Patients with moderate
 hypertension (MAP 100-120 mmHg) will be treated with transdermal nitroglycerin (0.2 mg/h) for
 48 hours. Patients with severe hypertension (MAP >120 mmHg) will also be treated with
 intravenous labetalol, to a target of <120 mmHg. Two hours after the baseline scan, MRI will
 be repeated. Any clinical or radiographic evidence of exacerbated oligemia associated with BP
 reduction will result in immediate discontinuation of all anti-hypertensive therapy. The
 effectiveness of BP control will be evaluated using a weighted mean average of MAP over 72
 hours. All patients will be re-imaged with MRI on day 3 to assess for hemorrhagic
 transformation. The primary endpoint is the change in objectively measured hypoperfused
 tissue volume between the baseline and 2 hour scans. Hypoperfused tissue will be determined
 as the volume of voxels with CBF ≤18 ml/100g/min, a previously validated measurement
 independent of observer variability. Sample size is based on power calculations required to
 detect a 10% change in oligemic tissue volume (which would be sufficient to result in
 exacerbation of ischemic injury) following MAP reduction.

 Preliminary Work: First, the investigators surveyed Canadian stroke neurologists about their
 current BP management practices. Indications for acute BP therapy in acute stroke varied from
 180 to 240 mmHg systolic, and few clinicians even considered diastolic or MAP treatment
 thresholds. Physicians based a generally conservative approach on the absence of evidence.
 Second, the investigators assessed the feasibility of serial MRI and MAP treatment protocols.
 To date, 9 patients have been imaged with repeat MRI, within 2 hours of the initial exam,
 confirming that the CBF≤18 ml/100g/min measures of at risk tissue volume can be used to
 monitor cerebral perfusion. Four patients were treated with our BP management protocol and
 imaged serially. MAP decreased in all 4 patients 2 hours after treatment. Increases in
 hypoperfused tissue volume (CBF≤18 ml/100g/min) following MAP reduction were generally mild
 (<10%). Of note, after BP reduction, the patient with the lowest initial MAP (96 mmHg) had a
 marked decline in CBF and large increase in volume of at risk tissue. Third, the
 investigators determined that decreases in CBF were always associated with increases in
 oxygen extraction, which appeared to protect tissue from infarct expansion because DWI lesion
 volumes remained stable. The variations in current practice and demonstration that reductions
 in MAP can lead to decreases CBF, potentially increasing the risk of adverse stroke-related
 outcomes justifies studies to determine appropriate treatment thresholds.

 Significance: The precise relationship between CBF and MAP in acute stroke must be elucidated
 prior to developing treatment thresholds for testing in a large randomized controlled trial.
 A serial perfusion study, with careful monitoring of MAP is a critical step in developing a
 rational BP management protocol. These findings will also help elucidate the mechanisms for
 poor outcome in patients with both high and low MAP at onset.
Inclusion Criteria:

 -  Acute ischemic stroke within 72 hours of symptom onset. In cases where onset time can
 not be established, it will be considered to be the time when the patient was last
 known to be well.

 -  18 years or older.

 -  Patients with Partial Anterior Circulation Infarcts (PACI; Oxfordshire Stroke
 Classification Project; OSCP) will be included.

 -  Patients with Posterior Circulation Infarcts (POCI) will be included only if there is
 evidence of cortical infarction in the territory of the posterior cerebral artery or
 its branches, including the occipital and mesial temporal lobes.

 Exclusion Criteria:

 -  Patients with a contraindication to the BP lowering protocol (i.e. known
 extracranial/intracranial arterial stenosis, high-grade stenotic valvular heart
 disease, or severe renal failure) will be ineligible, as will those with a definite
 indication for BP reduction (i.e. hypertensive encephalopathy, or aortic dissection).

 -  Patients with contraindications to MRI will be excluded, including metallic implants
 and any past sensitivity to gadolinium contrast media.

 -  Due to recent reports of nephrogenic systemic fibrosis associated with gadolinium
 exposure in individuals with pre-existing renal failure, patients with Creatinine >
 160 μmol/l or Glomerular Filtration Rate (GFR) <60 ml/min will also be excluded.

 -  Patients with renal artery stenosis will be excluded from this study, irrespective of
 renal function.

 -  Due to the possibility that oxygen therapy may confound CBF measurements, patients
 requiring >4 lpm to keep Sp02 ≥92% by nasal cannulae will be excluded.

 -  Patients with a suspected hemodynamic stroke mechanism will be ineligible. This will
 include patients with known or suspected hypotensive periods and/or a watershed
 territory of cerebral infarction seen on CT or MRI.

 -  Due to the possibility of increased susceptibility to BP reduction in patients with
 raised intracerebral pressure (ICP), those with evidence of significant mass effect
 secondary to acute infarction, including any degree of midline shift and/or
 ventricular compression will be ineligible. For the same reason, patients with head
 and eye deviation or other clinical evidence of a Total Anterior Circulation Infarct
 (TACI; OSCP) will also be ineligible.

 -  Due to technical difficulties associated with PWI in the posterior fossa, patients
 with brainstem and cerebellar strokes will be excluded.

 -  Patients with known sensitivity to nitroglycerin/labetalol/adhesives in nitroglycerin
 patches/ACE inhibitors/Angiotensin Receptor Blockers will be excluded.

 -  Amplification of the vasodilatory effects of topical nitroglycerin by
 phosphodiesterase inhibitors such as sildenafil or tadalafil can result in severe
 hypotension. Patients who have used either of these drugs within 12 h of initial
 assessment will therefore be excluded.